Key result
Renin-angiotensin system inhibitor use was significantly associated with enhanced survival in patients with ovarian cancer (HR 0.82; 95% CI 0.72-0.92).
Why the study?
The prognostic impact of renin-angiotensin system inhibitors on ovarian cancer remains indeterminate.
Does the use of renin-angiotensin system inhibitors improve survival in patients with ovarian cancer?
Meta-Analysis (n=14,634)
Does the use of renin-angiotensin system inhibitors improve survival in patients with ovarian cancer?
Hazard Ratio: 0.82 (95% CI 0.72–0.92)
In a meta-analysis of real-world data, the use of renin-angiotensin system inhibitors was associated with significantly improved overall survival in patients with ovarian cancer.
BACKGROUND: The prognostic impact of renin-angiotensin system inhibitors (RASIs) on ovarian cancer (OC) remains indeterminate. This meta-analysis aims to consolidate real-world data to provide a comprehensive, evidence-based assessment of the association between RASIs use and clinical outcomes in OC patients. METHODS: A meticulous search strategy was devised and executed across PubMed, Scopus, and Embase databases to retrieve all relevant studies evaluating the prognostic impact of RASIs in patients with OC. Studies comparing survival outcomes between RASIs users and non-users were included in the meta-analysis. RESULTS: A total of six studies, encompassing 11 cohorts and 14,634 patients, were included in the meta-analysis. RASIs use was found to be significantly correlated with enhanced survival (HR: 0.82; 95%CI: 0.72-0.92) in the OC patient population. Subgroup analysis showed that ACEIs use (HR: 0.83, 95% CI: 0.78-0.89) and post-diagnostic RASIs use (HR: 0.77, 95% CI: 0.66-0.90) significantly improved overall survival. CONCLUSION: This meta-analysis provides evidence that RASIs are associated with improved prognosis in OC patients. These findings suggest that RASIs may have potential as an adjunctive therapy in the management of OC, warranting further investigation and consideration in clinical management protocols.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted a meta-analysis in Ovarian cancer (n=14,634). Renin-angiotensin system inhibitors (RASIs) vs. Non-users was evaluated on Survival (HR 0.82, 95% CI 0.72-0.92). Renin-angiotensin system inhibitor use was significantly associated with enhanced survival in patients with ovarian cancer (HR 0.82; 95% CI 0.72-0.92).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: